SEC Form 4 · accession 0001104659-19-014626
Aridis Pharmaceuticals, Inc. · ARDS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Vu Truong
Officer — CEO and Director · Director
Period of report
Feb 20, 2019
Accepted (ET)
Mar 13, 2019 · 6:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001614067
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionsF1 | $8.46 | Feb 20, 2019 | A | 200,000 | A | — | Feb 20, 2029 | Common Stock | 200,000 | 316,861 | D |
Explanation of responses
- F1The Stock Options vest in equal installments over 48 months, beginning on March 20, 2019.